image: A new study harnesses genomic data to predict patients' risk of side effects from antidiabetic drugs. This material relates to a paper that appeared in the June 1, 2016 issue of Science Translational Medicine, published by AAAS. The paper, by R.A. Scott at University of Cambridge School of Clinical Medicine in Cambridge, UK, and colleagues was titled, "A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease." view more
Credit: C. Bickel / <i>Science Translational Medicine</i> (2016)